APA (7th ed.) Citation

HD, K., MH, R., YS, P., SY, L., M, M., & YK, K. (2022). Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 25(1), 226. https://doi.org/10.1007/s10120-021-01233-1

Chicago Style (17th ed.) Citation

HD, Kim, Ryu MH, Park YS, Lee SY, Moon M, and Kang YK. "Insertion-deletion Rate Is a Qualitative Aspect of the Tumor Mutation Burden Associated with the Clinical Outcomes of Gastric Cancer Patients Treated with Nivolumab." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 25, no. 1 (2022): 226. https://doi.org/10.1007/s10120-021-01233-1.

MLA (9th ed.) Citation

HD, Kim, et al. "Insertion-deletion Rate Is a Qualitative Aspect of the Tumor Mutation Burden Associated with the Clinical Outcomes of Gastric Cancer Patients Treated with Nivolumab." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, vol. 25, no. 1, 2022, p. 226, https://doi.org/10.1007/s10120-021-01233-1.